Sompraz%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520hp

# Sompraz HP (Pantoprazole) ## Overview Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by irreversibly inhibiting the H+/K+-ATPase enzyme system in gastric parietal cells. ## Primary Indications * Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD). * Maintenance of healing of erosive esophagitis. * Treatment of pathological hypersecretory conditions, including Zollinger-Ellison Syndrome (ZES). ## Adult Dosing * **Healing of Erosive Esophagitis:** 40 mg orally once daily for up to 8 weeks. A subsequent 8-week course may be considered for patients who have not healed after 8 weeks of treatment. * **Maintenance of Healing of Erosive Esophagitis:** 40 mg orally once daily. * **Pathological Hypersecretory Conditions (e.g., ZES):** Starting dose is typically 40 mg orally twice daily. Doses may be increased as clinically indicated. Doses greater than 40 mg twice daily should be administered with caution and titrated to the lowest dose that achieves the desired clinical effect. Doses up to 240 mg daily (divided into two doses) have been administered intravenously. Oral doses up to 200 mg daily have been administered as 100 mg twice daily. ## Pediatric Dosing * **Erosive esophagitis (1 month to 16 years):** * 5 years to 16 years: 20 mg orally once daily for up to 8 weeks. * 2 years to 5 years: 20 mg orally once daily for up to 8 weeks. * 1 month to 2 years: 1.0 to 1.3 mg/kg orally once daily, not to exceed 40 mg daily, for up to 8 weeks. * **Note:** Dosing in pediatric patients may vary. Consult specific pediatric guidelines or product labeling. ## Dose Adjustments * **Hepatic Impairment:** For patients with severe hepatic impairment, a dose of 20 mg once daily is recommended. * **Renal Impairment:** No dose adjustment is generally needed. ## Contraindications * Known hypersensitivity to pantoprazole, any other PPI, or any component of the formulation. ## Adverse Effects Common adverse effects include headache, diarrhea, nausea, abdominal pain, vomiting, dizziness, and flatulence. Long-term use of PPIs may be associated with an increased risk of fractures (hip, wrist, spine), Clostridium difficile infection, vitamin B12 deficiency, and hypomagnesemia. ## Key Drug Interactions * **Drugs dependent on gastric pH for absorption:** Pantoprazole can decrease absorption of drugs that require an acidic environment for proper absorption (e.g., ketoconazole, itraconazole, atazanavir, nelfinavir, iron salts). * **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity. * **CYP2C19 and CYP3A4 substrates:** Pantoprazole may affect the metabolism of drugs metabolized by these enzymes, though clinical significance is often uncertain. Examples include clopidogrel (reduced efficacy), warfarin (increased INR). ## Monitoring * Monitor for signs and symptoms of C. difficile-associated diarrhea. * Monitor magnesium levels, especially with prolonged therapy (>3 months) or concomitant diuretic use. * Consider monitoring vitamin B12 levels with prolonged therapy. * Monitor bone mineral density in patients at risk for osteoporosis. ## Clinical Pearls * Pantoprazole is generally taken 30-60 minutes before a meal. * For ZES and other hypersecretory conditions, dose titration is crucial, and patients may require higher doses or more frequent administration. * Long-term PPI use should be regularly reviewed for continued need and potential risks. * Pantoprazole is available in oral and intravenous formulations. *** *This information is intended for healthcare professionals. Always verify current prescribing information and consult with a qualified healthcare provider before making any decisions about patient care.*